Amgen Inc., of Thousand Oaks, Calif., reported revenue of $5.6 billion in the first quarter, bolstered by new and recently launched products, including cholesterol reducer Repatha (evolocumab), multiple myeloma treatment Kyprolis (carfilzomib), osteoporosis drug Prolia (denosumab) and bone metastasis drug Xgeva (denosumab), which all produced double-digit growth.